首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Integrin αIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells
【24h】

Integrin αIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells

机译:整合素αIIb启动子靶向基因产物在逆转录病毒转导的人类造血细胞衍生的巨核细胞中的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Megakaryocyte-specific expression of the platelet-adhesion receptor, integrin αIIbβ3, is caused by the presence of regulatory elements of the αIIb promoter that direct high-level, selective gene transcription early in megakaryocytopoiesis. To develop methods for targeted expression of transgenes, we transduced human CD34+ peripheral blood cells with a murine leukemia virus (MuLV) vector controlled by the human integrin αIIb promoter (nucleotides -889 to +35). A naturally occurring cDNA encoding the Pl~(A2) alloantigen form (Pro_(33)) of the integrin β3 subunit was subcloned into this construct (-889Pl~(A2)β3) and transduced into cells that endogenously synthesized Pl~(A1)β3 (Leu_(33)) as a marker for detection of provirus-derived β3. The ability of this vector to target expression of Pl~(A2)β3 to megakaryocytes was first examined in cell lines. Immunoblot analysis with human anti-Pl~(A2) alloserum detected synthesis of Pl~(A2)β3 in transduced promegakaryocytic cells; however, Pl~(A2)β3 protein was not detected in transduced epithelial cells. Human hematopoietic CD34+ cells were transduced with -889Pl~(A2)β3 virions and induced to differentiate with megakaryocyte growth and development factor. A hybrid αIIbβ3 complex was formed in progeny megakaryocytes where provirus-derived Pl~(A2)β3 was detected associated with endogenous αIIb subunit. Another αIIb promoter-driven MuLV vector (-889nlacZ) encoding Escherichia coli β-galactosidase was used to demonstrate that transgene expression was selectively targeted to the megakaryocyte progeny of transduced CD34+ cells. These studies demonstrate the feasibility of using αIIb promoter-driven MuLV vectors for gene transfer of hematopoietic CD34+ cells to target transgene expression in developing megakaryocytes and platelets and indicate potential applications toward human gene therapy for platelet disorders.
机译:血小板粘附受体整合素αIIbβ3的巨核细胞特异性表达是由αIIb启动子调控因子的存在引起的,该调控因子指导巨核细胞生成早期的高水平,选择性基因转录。为了开发转基因靶向表达的方法,我们用由人类整联蛋白αIIb启动子控制的鼠白血病病毒(MuLV)载体(核苷酸-889至+35)转导了人类CD34 +外周血细胞。将整合素β3亚基的P1〜(A2)同种异体抗原形式(Pro_(33))的天然存在的cDNA亚克隆到该构建体(-889P1〜(A2)β3)中,并转导到内源合成P1〜(A1)的细胞中β3(Leu_(33))作为检测前病毒来源的β3的标记。首先在细胞系中检查了该载体靶向P1〜(A2)β3向巨核细胞表达的能力。用人抗P1〜(A2)等位基因的免疫印迹分析检测到转导的巨核细胞中P1〜(A2)β3的合成;然而,在转导的上皮细胞中未检测到P1〜(A2)β3蛋白。用-889P1〜(A2)β3病毒粒子转导人类造血CD34 +细胞,并诱导其与巨核细胞生长和发育因子分化。在子代巨核细胞中形成了杂种αIIbβ3复合体,其中检测到前病毒衍生的Pl〜(A2)β3与内源性αIIb亚基相关。编码α-半乳糖苷酶的另一种由αIIb启动子驱动的MuLV载体(-889nlacZ)被用于证明转基因表达选择性地靶向了转导的CD34 +细胞的巨核细胞后代。这些研究证明了使用αIIb启动子驱动的MuLV载体进行造血CD34 +细胞的基因转移以靶向发展中的巨核细胞和血小板中的转基因表达的可行性,并表明了在人类基因治疗血小板疾病中的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号